WeTrials
Active, not recruiting

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

What is this study?

This study is testing an investigational weight-loss drug called maridebart cafraglutide to see how well it helps adults lose weight compared to a dummy treatment. It matters because it could lead to new, effective options for managing weight and overall health.

Who can participate?

You might be eligible if you are at least 18 years old, do not have diabetes, and have a high body mass index or a lower body mass index with a weight-related health condition. Participants should also have previously tried and struggled to lose weight through diet and exercise.

What will happen?

Participants will receive either the study drug or a placebo, which is an inactive substance that looks like real medicine. Researchers will closely monitor your weight changes, safety, and how your body tolerates the treatment.

Where and when?

The study takes place in locations across Alabama, United States. It is currently active and not recruiting new participants.

Key Points
  • 1Testing a new weight-loss drug called maridebart cafraglutide
  • 2For adults without diabetes who are overweight or have obesity
  • 3Comparing the study drug against an inactive placebo treatment

Related video

Radcliffe Cardiology: Dr Harold Bays on the MariTide phase 2 results before MARITIME-1 (June 2025)

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Obesity

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.